Connect with us

Hi, what are you looking for?

Monday, Jul 4, 2022
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Netherlands to give €1.4M for cannabis epilepsy research

The funding will be given to one party to determine the effectiveness of cannabis in children with epilepsy

Netherlands to give €1.4M for cannabis epilepsy research
Bedrocan is an EU GMP certified producer, and supplier of medical cannabis to the Dutch government. Image via Bedrocan

The Dutch government is issuing a second round of funding for medical cannabis research.

According to an official statement, the Ministry of Health, Welfare and Sport has commissioned the Netherlands Organization for Health Research and Development (ZonMw) to fund research that evaluates the effectiveness of medical cannabis in children.

This follows a round of €1.9 million provided by the Netherlands last November for research on cannabis as treatment for neuropathic pain.

It also comes after another study published in December that showed a combination of CBD and THC products reduced seizures in almost all patients in a small group of 10 children with epilepsy.

The new research will aim to confirm that medical cannabis reduces the frequency or severity of seizures in children with treatment-resistant epilepsy. Secondary topics include quality of life, side effects and cost.

ZonMw says the funds will be awarded to one party that will address the research points in an integrated plan. That party will also have relevant experience in clinical research with children.

Read more: Switzerland allows doctors to directly prescribe medical cannabis

Read more: Morocco moves to legalize cannabis for medical and industrial use

A maximum of €1.4 million (around C$2.1 million) is available for a project with a maximum span of four years. Part of the budget must be used to produce a standard research product.

For the research awarded last year, the product was supplied by Bedrocan. The EU GMP certified producer is a supplier of medical cannabis to the Dutch government and makes a high-CBD product called Bedrolite.

Following a June 2020 epilepsy guideline, pharmaceutical cannabidiol can be prescribed to Dutch children from 2–18 years old with treatment-resistant Dravet syndrome or Lennox-Gastaut syndrome.

Oil made from Bedrolite is sold to these patients in the Netherlands and several other countries. According to Bedrocan, at the beginning of this year the Dutch Medicines Evaluation Board put cannabidiol used by patients with epilepsy on a list of medicines where switching manufacturers isn’t recommended.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Follow Nick Laba on Twitter

Click to comment

Leave a Reply

Your email address will not be published.

You May Also Like

Health and Safety

Science doesn't know yet, but one psychedelic researcher is chasing clues to see if it can


As more medium-to-small producers came into play this year, great weed started hitting legal shelves at fairer prices


Punishments for possession include caning and the death penalty. Despite a global trend of reform, The Fine City remains staunch in its anti-drug stance


While legal weed businesses decry enforcement of their accounts, the platform says it's keeping its all-ages community safe